Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis

Clinical Infectious Diseases

Volumn 40, Issue 12, 2005, Pages 1748-1755

  Casey, Janet R ^a,b   Pichichero, Michael E ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Elmwood Pediatric Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFACLOR; CLARITHROMYCIN; ERYTHROMYCIN ESTOLATE; MACROLIDE; PENICILLIN V; ROXITHROMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; ERADICATION THERAPY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NONHUMAN; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; SYSTEMATIC REVIEW; TONSILLITIS; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; HUMANS; PHARYNGITIS; RANDOMIZED CONTROLLED TRIALS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TONSILLITIS;

EID: 20444385144     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430307     Document Type: Article

References (59)

1. Krober MS, Bass JW, Michels GN. Streptococcal pharyngitis: placebo-controlled double-blind evaluation of clinical response to penicillin therapy. JAMA 1985; 253:1271-4.
2. Nelson JD. The effect of penicillin therapy on the symptoms and signs of streptococcal pharyngitis. Pediatr Infect Dis 1984; 3:10-3.
3. Wannamaker LW, Rammelkamp CH Jr, Denny FW, et al. Prophylaxis of acute rheumatic fever by treatment of the preceeding streptococcal infection with various amounts of depot penicllin. Am J Med 1951; 10:673-95.
4. Wannamaker LW, Denny FW, Perry WD, et al. The effect of penicillin prophylaxis on streptococcal disease rates and the carrier state. N Engl J Med 1953; 249:1-7.
5. Denny FW, Wannamaker LW, Brink WR, Rammelkamp CH Jr, Custer EA. Prevention of rheumatic fever. JAMA 1950; 143:151-3.
6. Breese BB. Treatment of betahemolytic streptococcic infections in the home. JAMA 1953; 152:10-4.
7. Breese BB, Denny FW, Dillon HC, et al. Consensus: difficult management problems in children with streptococcal pharyngitis. Pediatr Infect Dis 1985; 4:10-3.
8. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002; 35:113-25.
9. Vukmir RB. Adult and pediatric pharyngitis: a review. J Emerg Med 1992; 10:607-16.
10. Jacoby GA. Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clin Infect Dis 1994; 18:951-7.
11. Pichichero ME. Controversies in the treatment of streptococcal pharyngitis. Am Fam Physician 1990; 42:1567-76.
12. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother 1993; 31(Suppl E):111-7.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996; 17:1-12.
14. Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. J Clin Epidemiol 1995; 48:23-40.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-88.
16. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309:1351-5.
17. Petitti DB. Approaches to heterogeneity in meta-analysis. Stat Med 2001; 20:3625-33.
18. Hamill J. Multicentre evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 1993; 31(Suppl E):89-94.
19. Weippl G. Multicentre comparison of azithromycin versus erythromycin in the treatment of paediatric pharyngitis or tonsillitis caused by group A streptococci. J Antimicrob Chemother 1993; 31(Suppl E): 95-101.
20. Pacifico L, Scopetti F, Ranucci A, et al. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A β-hemolytic streptococcal pharyngitis in children. Antimicrob Agents Chemother 1996; 40:1005-8.
21. Schaad UB, Heynen G. Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group. Pediatr Infect Dis J 1996; 15:791-5.
22. O'Doherty B. Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1996; 15:718-24.
23. Padilla-Raygoza N. Comparison of clarithromycin and azithromycin for treatment of streptococcal pharyngotonsillitis in children. Infect Med 1998; 15(Suppl. D):23-7.
24. Garcia Callejo FJ, Velert Vila MM, Orts Alborch MH, Pardo Mateu L, Esparcia Navarro M. Comparison of azithromycin, amoxicillin/clavulanic acid and cefaclor in the treatment of acute ENT infections [in Spanish]. Acta Otorrinolaringol Esp 1998; 49:306-12.
25. Venuta A, Laudizi L, Beverelli A, et al. Azithromycin compared with clarithromycin for the treatment of streptococcal pharyngitis in children. J Int Med Res 1998; 26:152-8.
26. Cremer J, Wallrauch C, Milatovic D, Braveny I. Azithromycin versus cefaclor in the treatment of pediatric patients with acute group A β-hemolytic streptococcal tonsillopharyngitis. Eur J Clin Microbiol Infect Dis 1998; 17:235-9.
27. Cohen R, Reinert P, De La Rocque F, et al. Comparison of two dosages of azithromycin for three days versus penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2002; 21:297-303.
28. Schaad UB, Kellerhals P, Altwegg M. Azithromycin versus penicillin V for treatment of acute group A streptococcal pharyngitis. Pediatr Infect Dis J 2002; 21:304-8.
29. Still JG. Azithromycin suspension vs. penicillin suspension in treatment of children with streptococcal pharyngitis [abstract PII-101]. Clin Pharm Ther 1993; 53:195.
30. Still JG. Management of pediatric patients with group A beta-hemolytic streptococcus pharyngitis: treatment options. Pediatr Infect Dis 1995; 14:S57-61.
31. Still JG. Treatment of streptococci pharyngitis in children with five days of azithromycin suspension [abstract M67]. In: Proceedings and abstracts of the 34th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, Florida). 1994.
32. Muller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 1993; 31(Suppl E):137-46.
33. Muller O. An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections. J Antimicrob Chemother 1996; 37(Suppl C):83-92.
34. O'Doherty B. An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 1996; 37(Suppl C):71-81.
35. Hooton TM. A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am J Med 1991; 91:23S-6S.
36. Kaplan EL, Gooch Iii Wm, Notario GF, Craft JC. Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin). Clin Infect Dis 2001; 32:1798-802.
37. Lee LH, Ayoub E, Pichichero ME. Fewer symptoms occur in same-serotype recurrent streptococcal tonsillopharyngitis. Arch Otolaryngol Head Neck Surg 2000; 126:1359-62.
38. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports from meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 1999; 354:1896-900.
39. Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352:609-13.
40. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by simple, graphical test. BMJ 1997; 315:629-34.
41. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408-12.
42. Klassen TP, Wiebe N, Russell KL, et al. Abstracts of randomized controlled trials presented at the society for pediatric research meeting. Arch Pediatr Adolesc Med 2002; 156:474-9.
43. Shulman ST, Gerber MA. So what's wrong with penicillin for strep throat? Pediatrics 2004; 113:1816-9.
44. Mohler DN, Wallin DG, Dreyfus EG. Studies in the home treatment of streptococcal disease I: failure of patients to take penicillin by mouth as prescribed. N Engl J Med 1955; 252:1116-8.
45. Bergman AB, Werner RJ. Failure of children to receive penicillin by mouth. N Engl J Med 1963; 268:1334-8.
46. Leistyna JA, Macaulay JC. Therapy of streptococcal infections: do pediatric patients receive prescribed oral medication? Amer J Dis Child 1966; 111:22-6.
47. Charney E, Bynum R, Eldredge D, et al. How well do patients take oral penicillin? A collaborative study in private practice. Pediatrics 1967; 40:188-95.
48. Green JL, Ray SP, Charney E. Recurrence rate of streptococcal pharyngitis related to oral penicillin. J Pediatr 1969; 75:292-4.
49. Schwartz RH, Rodriquez WJ, Grundfast KM. Pharmacologic compliance with antibiotic therapy for acute otitis media: influence on subsequent middle ear effusion. Pediatrics 1981; 68:619-22.
50. Finney JW, Friman PC, Rapoff MA, Christophersen ER. Improving compliance with antibiotic regimens for otitis media. Am J Dis Child 1985; 139:89-95.
51. Cohen R. Defining the optimum treatment regimen for azithromycin in acute tonsillopharyngitis. Pediatr Infect Dis J 2004; 23(2 Suppl): S129-34.
52. Gooch WM, Blair E, Puopolo A, et al. Effectiveness of five days of therapy with cefuroxime axetil suspension for treatment of acute otitis media. Pediatric Infect Dis J 1996; 15:157-64.
53. Gehanno P, Taillebe M, Denis P, et al. Short course cefotaxime compared with 5-day co-amoxyclav in acute otitis media in children. J Antimicrob Chemother 1990; 26(Suppl A):29-36.
54. Syrogiannopoulos GA, Grivea IN, Fitoussi F, et al. High prevalence of erythromycin resistance of Streptococcus pyogenes in Greek children. Pediatr Infect Dis J 2001; 20:863-8.
55. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002; 346:1200-6.
56. Dicuonzo G, Fiscarelli E, Gherardi G, et al. Erythromycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in Italy. Antimicrob Agents Chemother 2002; 46:3987-90.
57. Reinert RR, Lutticken R, Bryskier A, Al-Lahham A. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob Agents Chemother 2003; 47:489-93.
58. Bergman M, Huikko S, Pihlajamaki M, et al. Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. Clin Infect Dis 2004; 38:1251-6.
59. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin resistant Streptococcus pneumoniae. JAMA 1998; 279:365-70.